Martin Rowe

List of Publications by Year
in descending order

151 papers	14,618 citations	15504 65 h-index	20358 116 g-index
153 all docs	153 docs citations	153 times ranked	8751 citing authors

#	Article	IF	Citations
1	Induction of bcl-2 expression by epstein-barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell, 1991, 65, 1107-1115.	28.9	1,219
2	Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature, 2012, 490, 116-120.	27.8	759
3	Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet, The, 1991, 337, 320-322.	13.7	707
4	Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 8479-8483.	7.1	601
5	Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies.. Journal of Experimental Medicine, 1992, 176, 157-168.	8.5	504
6	Expression of Epsteinâ€Barr virusâ€encoded proteins in nasopharyngeal carcinoma. International Journal of Cancer, 1988, 42, 329-338.	5.1	483
7	Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23.. Proceedings of the National Academy of Sciences of the United States of America, 1987, 84, 3452-3456.	7.1	444
8	Different Epstein--Barr virus--B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. Journal of General Virology, 1990, 71, 1481-1495.	2.9	341
9	Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man.. Journal of Experimental Medicine, 1991, 173, 147-158.	8.5	313
10	Monoclonal Antibodies to the Latent Membrane Protein of Epstein-Barr Virus Reveal Heterogeneity of the Protein and Inducible Expression in Virus-transformed Cells. Journal of General Virology, 1987, 68, 1575-1586.	2.9	298
11	HLA-A11 epitope loss isolates of Epstein-Barr virus from a highly A11+ population. Science, 1993, 260, 98-100.	12.6	272
12	Epsteinâ€‰â€“â€‰Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-ÎºB pathway involving TNF receptor-associated factors. Oncogene, 1997, 14, 2899-2916.	5.9	252
13	Host shutoff during productive Epstein-Barr virus infection is mediated by BGLF5 and may contribute to immune evasion. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3366-3371.	7.1	202
14	Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression. European Journal of Immunology, 1995, 25, 1374-1384.	2.9	195
15	Epstein-Barr Virus-Encoded Latent Membrane Protein 1 Activates the JNK Pathway through Its Extreme C Terminus via a Mechanism Involving TRADD and TRAF2. Journal of Virology, 1999, 73, 1023-1035.	3.4	194
16	The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer. Nature Medicine, 1995, 1, 464-470.	30.7	184
17	Epstein-barr virus-infected b cells persist in the circulation of acyclovir-treated virus carriers. International Journal of Cancer, 1989, 43, 67-71.	5.1	181
18	Restricted Epstein-Barr virus protein expression in Burkitt lymphoma is due to a different Epstein-Barr nuclear antigen 1 transcriptional initiation site.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 6343-6347.	7.1	181

#	Article	IF	Citations
19	Monoclonal antibodies to epstein-barr virus-induced, transformation-associated cell surface antigens: Binding patterns and effect upon virus-specific t-cell cytotoxicity. International Journal of Cancer, 1982, 29, 373-381.	5.1	156
20	Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in <i>p53</i>. Genes and Development, 2014, 28, 58-70.	5.9	156
21	Epsteinâ€“Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T-cell surveillance. Nature, 1985, 317, 629-631.	27.8	149
22	The Epstein-Barr Virus G-Protein-Coupled Receptor Contributes to Immune Evasion by Targeting MHC Class I Molecules for Degradation. PLoS Pathogens, 2009, 5, e1000255.	4.7	149
23	An Epstein-Barr Virus Anti-Apoptotic Protein Constitutively Expressed in Transformed Cells and Implicated in Burkitt Lymphomagenesis: The Wp/BHRF1 Link. PLoS Pathogens, 2009, 5, e1000341.	4.7	142
24	Epstein-Barr Virus Nuclear Antigen 3C Interacts with Histone Deacetylase To Repress Transcription. Journal of Virology, 1999, 73, 5688-5697.	3.4	136
25	The Switch from Latent to Productive Infection in Epstein-Barr Virus-Infected B Cells Is Associated with Sensitization to NK Cell Killing. Journal of Virology, 2007, 81, 474-482.	3.4	134
26	The H3K27me3 demethylase, KDM6B, is induced by Epsteinâ€“Barr virus and over-expressed in Hodgkin's Lymphoma. Oncogene, 2011, 30, 2037-2043.	5.9	133
27	T-cell-mediated regression of â€œspontaneousâ€•and of Epstein-Barr virus-induced B-cell transformation in vitro: Studies with cyclosporin A. Cellular Immunology, 1984, 87, 646-658.	3.0	132
28	Immunohistochemical demonstration of the Epstein-Barr virus-encoded latent membrane protein in paraffin sections of Hodgkin's disease. Journal of Pathology, 1992, 166, 1-5.	4.5	131
29	Cytostatic Effect of Epsteinâ€“Barr Virus Latent Membrane Protein-1 Analyzed Using Tetracycline-Regulated Expression in B Cell Lines. Virology, 1996, 223, 29-40.	2.4	130
30	Ligation of the CD23, p45 (BLAST-2, EBVCS) antigen triggers the cell-cycle progression of activated B lymphocytes. European Journal of Immunology, 1986, 16, 1075-1080.	2.9	127
31	Distinctions between endemic and sporadic forms of epstein-barr virus-positive burkitt's lymphoma. International Journal of Cancer, 1985, 35, 435-441.	5.1	126
32	Three transcriptionally distinct forms of epstein-barr virus latency in somatic cell hybrids: Cell phenotype dependence of virus promoter usage. Virology, 1992, 187, 189-201.	2.4	120
33	Epstein-Barr virus latent membrane protein-1 (LMP1) C-terminus activation region 2 (CTAR2) maps to the far C-terminus and requires oligomerisation for NF-Î°B activation. Oncogene, 1997, 15, 1851-1858.	5.9	119
34	Human cytotoxic T-cell responses against Epstein-Barr virus nuclear antigens demonstrated by using recombinant vaccinia viruses.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 2906-2910.	7.1	114
35	The Epstein--Barr virus carrier state: dominance of a single growth-transforming isolate in the blood and in the oropharynx of healthy virus carriers. Journal of General Virology, 1991, 72, 1579-1590.	2.9	112
36	Expression of Epstein-Barr virus replicative proteins in aids-related non-Hodgkin's lymphoma cells. Journal of Pathology, 1991, 165, 289-299.	4.5	111

#	Article	IF	Citations
37	Epstein-Barr virus evasion of CD8+ and CD4+ T cell immunity via concerted actions of multiple gene products. Seminars in Cancer Biology, 2008, 18, 397-408.	9.6	108
38	Epsteinâ€"Barr virus-specific cytotoxic T-cell clones restricted through a single HLA antigen. Nature, 1982, 297, 413-415.	27.8	106
39	Features Distinguishing Epstein-Barr Virus Infections of Epithelial Cells and B Cells: Viral Genome Expression, Genome Maintenance, and Genome Amplification. Journal of Virology, 2009, 83, 7749-7760.	3.4	104
40	Epstein-Barr virus status and tumour cell phenotype in sporadic Burkitt's lymphoma. International Journal of Cancer, 1986, 37, 367-373.	5.1	102
41	Antigen Processing Defects in Cervical Carcinomas Limit the Presentation of a CTL Epitope from Human Papillomavirus 16 E6. Journal of Immunology, 2001, 167, 5420-5428.	0.8	101
42	Evidence for an association between CD23 and the receptor for a low molecular weight B cell growth factor. European Journal of Immunology, 1986, 16, 1627-1630.	2.9	100
43	Quantitative Studies of Epstein-Barr Virus-Encoded MicroRNAs Provide Novel Insights into Their Regulation. Journal of Virology, 2011, 85, 996-1010.	3.4	99
44	Burkitt's lymphoma: The Rosetta Stone deciphering Epstein-Barr virus biology. Seminars in Cancer Biology, 2009, 19, 377-388.	9.6	94
45	Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised.. Journal of Experimental Medicine, 1995, 181, 2221-2228.	8.5	91
46	Epstein-Barr virus LMP1 blocks p16INK4aâ€"RB pathway by promoting nuclear export of E2F4/5. Journal of Cell Biology, 2003, 162, 173-183.	5.2	91
47	Bmi-1 is induced by the Epstein-Barr virus oncogene LMP1 and regulates the expression of viral target genes in Hodgkin lymphoma cells. Blood, 2007, 109, 2597-2603.	1.4	89
48	Epstein-Barr Virus Infection of Polarized Epithelial Cells via the Basolateral Surface by Memory B Cell-Mediated Transfer Infection. PLoS Pathogens, 2011, 7, e1001338.	4.7	89
49	The DNase of Gammaherpesviruses Impairs Recognition by Virus-Specific CD8⁺T Cells through an Additional Host Shutoff Function. Journal of Virology, 2008, 82, 2385-2393.	3.4	87
50	The bfl-1 Gene Is Transcriptionally Upregulated by the Epstein-Barr Virus LMP1, and Its Expression Promotes the Survival of a Burkitt's Lymphoma Cell Line. Journal of Virology, 2000, 74, 6652-6658.	3.4	86
51	Down-regulation of BLIMP1Î± by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: implications for the pathogenesis of EBV-associated B-cell lymphomas. Blood, 2011, 117, 5907-5917.	1.4	86
52	Epstein-Barr Virus Nuclear Antigen 3C and Prothymosin Alpha Interact with the p300 Transcriptional Coactivator at the CH1 and CH3/HAT Domains and Cooperate in Regulation of Transcription and Histone Acetylation. Journal of Virology, 2002, 76, 4699-4708.	3.4	83
53	Epstein-Barr Virus gp42 Is Posttranslationally Modified To Produce Soluble gp42 That Mediates HLA Class II Immune Evasion. Journal of Virology, 2005, 79, 841-852.	3.4	82
54	PATTERNS OF EPSTEIN-BARR VIRUS LATENT AND REPLICATIVE GENE EXPRESSION IN EPSTEIN-BARR VIRUS B CELL LYMPHOPROLIFERATIVE DISORDERS AFTER ORGAN TRANSPLANTATION. Transplantation, 1994, 58, 317-323.	1.0	82

#	Article	IF	Citations
55	Epigenetic and Transcriptional Changes Which Follow Epstein-Barr Virus Infection of Germinal Center B Cells and Their Relevance to the Pathogenesis of Hodgkin's Lymphoma. Journal of Virology, 2011, 85, 9568-9577.	3.4	81
56	Stage-Specific Inhibition of MHC Class I Presentation by the Epstein-Barr Virus BNLF2a Protein during Virus Lytic Cycle. PLoS Pathogens, 2009, 5, e1000490.	4.7	80
57	The Epstein-Barr Virus-Encoded BILF1 Protein Modulates Immune Recognition of Endogenously Processed Antigen by Targeting Major Histocompatibility Complex Class I Molecules Trafficking on both the Exocytic and Endocytic Pathways. Journal of Virology, 2011, 85, 1604-1614.	3.4	74
58	Epstein-Barr virus-transformed human precursor B cell lines: altered growth phenotype of lines with germline or rearranged but nonexpressed heavy chain genes. European Journal of Immunology, 1987, 17, 1199-1207.	2.9	71
59	Downregulated Expression of SHP-1 in Burkitt Lymphomas and Germinal Center B Lymphocytes. Journal of Experimental Medicine, 1997, 186, 1575-1583.	8.5	71
60	Impaired Transporter Associated with Antigen Processing-Dependent Peptide Transport during Productive EBV Infection. Journal of Immunology, 2005, 174, 6829-6838.	0.8	70
61	Reactivation of epstein-barr virus-specific cytotoxic t cells byin vitro stimulation with the autologous lymphoblastoid cell line. International Journal of Cancer, 1981, 27, 593-601.	5.1	69
62	Viral latent membrane protein 1 (LMP-1)â€“induced CD99 down-regulation in B cells leads to the generation of cells with Hodgkin's and Reed-Sternberg phenotype. Blood, 2000, 95, 294-300.	1.4	69
63	The Lytic Cycle of Epstein-Barr Virus Is Associated with Decreased Expression of Cell Surface Major Histocompatibility Complex Class I and Class II Molecules. Journal of Virology, 2002, 76, 8179-8188.	3.4	69
64	Cytotoxic T cell recognition of Epstein-Barr virus-infected B cells. III. Establishment of HLA-restricted cytotoxic T cell lines using interleukin 2. European Journal of Immunology, 1982, 12, 1012-1018.	2.9	68
65	Unexpected patterns of Epsteinâ€“Barr virus transcription revealed by a High throughput PCR array for absolute quantification of viral mRNA. Virology, 2015, 474, 117-130.	2.4	68
66	The role of repetitive DNA sequences in the size variation of Epstein--Barr virus (EBV) nuclear antigens, and the identification of different EBV isolates using RFLP and PCR analysis. Journal of General Virology, 1995, 76, 779-790.	2.9	67
67	Latent Membrane Protein 1 of Epstein-Barr Virus Stimulates Processing of NF-Î°B2 p100 to p52. Journal of Biological Chemistry, 2003, 278, 51134-51142.	3.4	66
68	Epstein-Barr Virus LMP-1 Natural Sequence Variants Differ in Their Potential To Activate Cellular Signaling Pathways. Journal of Virology, 2001, 75, 9129-9141.	3.4	65
69	Two Carboxyl-terminal Activation Regions of Epstein-Barr Virus Latent Membrane Protein 1 Activate NF-Î°B through Distinct Signaling Pathways in Fibroblast Cell Lines. Journal of Biological Chemistry, 2003, 278, 46565-46575.	3.4	65
70	Epstein Barr virus entry; kissing and conjugation. Current Opinion in Virology, 2014, 4, 78-84.	5.4	65
71	A novel latent membrane 2 transcript expressed in Epstein-Barr virusâ€“positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy. Blood, 2010, 116, 3695-3704.	1.4	63
72	The Missing Link in Epstein-Barr Virus Immune Evasion: the BDLF3 Gene Induces Ubiquitination and Downregulation of Major Histocompatibility Complex Class I (MHC-I) and MHC-II. Journal of Virology, 2016, 90, 356-367.	3.4	63

#	Article	IF	Citations
73	Epstein-Barr Virus Evades CD4+ T Cell Responses in Lytic Cycle through BZLF1-mediated Downregulation of CD74 and the Cooperation of vBcl-2. PLoS Pathogens, 2011, 7, e1002455.	4.7	61
74	Epsteinâ€“Barr virus latent membrane protein-1 (LMP1) signalling is distinct from CD40 and involves physical cooperation of its two C-terminus functional regions. Oncogene, 1998, 17, 2383-2392.	5.9	59
75	Precipitation of the Epstein--Barr virus protein EBNA 2 by an EBNA 3c-specific monoclonal antibody. Journal of General Virology, 1994, 75, 769-778.	2.9	58
76	Latent Membrane Protein 1 Inhibits Epstein-Barr Virus Lytic Cycle Induction and Progress via Different Mechanisms. Journal of Virology, 2003, 77, 5000-5007.	3.4	58
77	Stimulation of human lymphocytes with irradiated cells of the autologous Epstein-Barr virus-transformed cell line. Cellular Immunology, 1982, 67, 129-140.	3.0	57
78	Phosphatidylinositol 3-kinase is essential for the proliferation of lymphoblastoid cells. Oncogene, 2002, 21, 1263-1271.	5.9	55
79	Epstein-Barr virus and Burkitt lymphoma. Chinese Journal of Cancer, 2014, 33, 609-19.	4.9	54
80	Epstein-Barr Virus and Carcinomas Expression of the Viral Genome in an Undifferentiated Gastric Carcinoma. Diagnostic Molecular Pathology, 1992, 1, 103-108.	2.1	53
81	Nuclear Factor Î°B-Dependent Activation of the Antiapoptotic bfl - 1 Gene by the Epstein-Barr Virus Latent Membrane Protein 1 and Activated CD40 Receptor. Journal of Virology, 2004, 78, 1800-1816.	3.4	52
82	Epsteinâ€Barr Virusâ€“Associated Hemophagocytic Lymphohistiocytosis in Adults Characterized by High Viral Genome Load within Circulating Natural Killer Cells. Clinical Infectious Diseases, 2010, 51, 66-69.	5.8	51
83	The 30-Base-Pair Deletion in Chinese Variants of the Epstein-Barr Virus LMP1 Gene Is Not the Major Effector of Functional Differences between Variant LMP1 Genes in Human Lymphocytes. Journal of Virology, 1998, 72, 4038-4048.	3.4	51
84	The epstein-barr virus: Host balance in acute infectious mononucleosis patients receiving acyclovir anti-viral therapy. International Journal of Cancer, 1989, 43, 61-66.	5.1	50
85	Mechanism of Action of a Novel Latent Membrane Protein-1 Dominant Negative. Journal of Biological Chemistry, 2001, 276, 1195-1203.	3.4	49
86	Cooperation between Epstein-Barr Virus Immune Evasion Proteins Spreads Protection from CD8+ T Cell Recognition across All Three Phases of the Lytic Cycle. PLoS Pathogens, 2014, 10, e1004322.	4.7	47
87	HIV-1 Induces Down-Regulation of bcl-2 Expression and Death by Apoptosis of EBV-Immortalized B Cells: A Model for a Persistent "Self-Limiting" HIV-1 Infection. Virology, 1994, 198, 234-244.	2.4	46
88	Immune responses to Epsteinâ€“Barr virus: molecular interactions in the virus evasion of CD8+ T cell immunity. Microbes and Infection, 2010, 12, 173-181.	1.9	46
89	Isolation of a normal B cell subset with a Burkitt-like phenotype and transformationin vitro with Epstein-Barr virus. International Journal of Cancer, 1988, 42, 213-220.	5.1	45
90	Lymphotoxin acts as an autocrine growth factor for Epstein-Barr virus-transformed B cells and differentiated Burkitt lymphoma cell lines. European Journal of Immunology, 1994, 24, 1879-1885.	2.9	45

#	Article	IF	Citations
91	Characterization of the Serological Response in Man to the Latent Membrane Protein and the Six Nuclear Antigens Encoded by Epstein-Barr Virus. Journal of General Virology, 1988, 69, 1217-1228.	2.9	44
92	Deciphering the role of Epstein-Barr virus in the pathogenesis of T and NK cell lymphoproliferations. Herpesviridae, 2011, 2, 8.	2.7	40
93	Characterization of Intercellular Adhesion Molecule-1 Regulation by Epstein-Barr Virus-encoded Latent Membrane Protein-1 Identifies Pathways That Cooperate with Nuclear Factor ÎºB to Activate Transcription. Journal of Biological Chemistry, 2001, 276, 984-992.	3.4	38
94	Epsteinâ€"Barr virus transcription factor Zta acts through distal regulatory elements to directly control cellular gene expression. Nucleic Acids Research, 2015, 43, 3563-3577.	14.5	37
95	EBV BCL-2 homologue BHRF1 drives chemoresistance and lymphomagenesis by inhibiting multiple cellular pro-apoptotic proteins. Cell Death and Differentiation, 2020, 27, 1554-1568.	11.2	35
96	Cyclical Expression of EBV Latent Membrane Protein 1 in EBV-Transformed B Cells Underpins Heterogeneity of Epitope Presentation and CD8+ T Cell Recognition. Journal of Immunology, 2009, 182, 1919-1928.	0.8	31
97	Modulation of B-cell endoplasmic reticulum calcium homeostasis by Epstein-Barr virus Latent Membrane Protein-1. Molecular Cancer, 2009, 8, 59.	19.2	31
98	Epstein-Barr Virus Latent Membrane Protein 1 Increases Calcium Influx through Store-operated Channels in B Lymphoid Cells. Journal of Biological Chemistry, 2011, 286, 18583-18592.	3.4	31
99	Suppression of the <scp>LMP2A</scp> target gene, <i><scp>EGR</scp>â€1</i>, protects Hodgkin's lymphoma cells from entry to the <scp>EBV</scp> lytic cycle. Journal of Pathology, 2013, 230, 399-409.	4.5	31
100	Memory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation event. Blood, 2015, 126, 2665-2675.	1.4	31
101	Counteracting Effects of Cellular Notch and Epstein-Barr Virus EBNA2: Implications for Stromal Effects on Virus-Host Interactions. Journal of Virology, 2014, 88, 12065-12076.	3.4	29
102	Innate Immune Recognition of EBV. Current Topics in Microbiology and Immunology, 2015, 391, 265-287.	1.1	29
103	Epstein-Barr Virus Regulates STAT1 through Latent Membrane Protein 1. Journal of Virology, 2003, 77, 4439-4443.	3.4	28
104	Epstein-Barr Virus Represses the FoxO1 Transcription Factor through Latent Membrane Protein 1 and Latent Membrane Protein 2A. Journal of Virology, 2006, 80, 11191-11199.	3.4	27
105	Effect of the ebna-2 gene on the surface antigen phenotype of transfected ebv-negative B-lymphoma lines. International Journal of Cancer, 1990, 45, 77-82.	5.1	26
106	Induction of the Lytic Cycle Sensitizes Epstein-Barr Virus-Infected B Cells to NK Cell Killing That Is Counteracted by Virus-Mediated NK Cell Evasion Mechanisms in the Late Lytic Cycle. Journal of Virology, 2016, 90, 947-958.	3.4	26
107	Sphingosine-1-phosphate signalling drives an angiogenic transcriptional programme in diffuse large B cell lymphoma. Leukemia, 2019, 33, 2884-2897.	7.2	26
108	Herpesviruses Placating the Unwilling Host: Manipulation of the MHC Class II Antigen Presentation Pathway. Viruses, 2012, 4, 1335-1353.	3.3	25

#	Article	IF	Citations
109	Epstein-Barr Virus and the Pathogenesis of T and NK Lymphoma: a Mystery Unsolved. Current Hematologic Malignancy Reports, 2012, 7, 276-284.	2.3	25
110	Isolation and analysis of two strongly transforming isoforms of the Epstein-Barr-virus(EBV)-encoded latent membrane protein-1 (LMP1) from a single Hodgkin's lymphoma. , 1998, 76, 194-200.		22
111	CD99 expression is positively regulated by Sp1 and is negatively regulated by Epstein-Barr virus latent membrane protein 1 through nuclear factor-Î°B. Blood, 2001, 97, 3596-3604.	1.4	22
112	Coordinated repression of BIM and PUMA by Epsteinâ€“Barr virus latent genes maintains the survival of Burkitt lymphoma cells. Cell Death and Differentiation, 2018, 25, 241-254.	11.2	20
113	Viral latent membrane protein 1 (LMP-1)â€“induced CD99 down-regulation in B cells leads to the generation of cells with Hodgkin's and Reed-Sternberg phenotype. Blood, 2000, 95, 294-300.	1.4	20
114	Epstein-Barr virus gene expression in post-transplant lymphoproliferative disorders. Seminars in Immunopathology, 1998, 20, 389-403.	4.0	18
115	Kaposi's Sarcoma-Associated Herpesvirus-Encoded Viral IRF3 Modulates Major Histocompatibility Complex Class II (MHC-II) Antigen Presentation through MHC-II Transactivator-Dependent and -Independent Mechanisms: Implications for Oncogenesis. Journal of Virology, 2013, 87, 5340-5350.	3.4	18
116	Identification of Epstein-Barr Virus Replication Proteins in Burkittâ€™s Lymphoma Cells. Pathogens, 2015, 4, 739-751.	2.8	17
117	Establishment of an EBV-positive lymphoblastoid cell line that grows as a lymphoma in nude mice and expresses membrane CD2 molecules. International Journal of Cancer, 1990, 45, 299-307.	5.1	15
118	Reduced Signal Transduction through Glucocorticoid Receptor in Burkitt's Lymphoma Cell Lines. Virology, 1994, 199, 339-353.	2.4	15
119	Epstein-Barr Virus Latent Membrane Protein-1 Mediates Upregulation of Tumor Necrosis Factor-α in EBV-Infected T Cells: Implications for the Pathogenesis of Hemophagocytic Syndrome. Journal of Biomedical Science, 2003, 10, 146-155.	7.0	15
120	Epsteinâ€“Barr virus induces a distinct form of DNA-bound STAT1 compared with that found in interferon-stimulated B lymphocytes. Journal of General Virology, 2007, 88, 1876-1886.	2.9	15
121	Epstein-Barr Virus and Carcinomas Expression of the Viral Genome in an Undifferentiated Gastric Carcinoma. Diagnostic Molecular Pathology, 1992, 1, 103-108.	2.1	14
122	NF-Î°B is required for cell death induction by latent membrane protein 1 of Epsteinâ€“Barr virus. Cellular Signalling, 2003, 15, 423-433.	3.6	14
123	CD154 Tone Sets the Signaling Pathways and Transcriptome Generated in Model CD40-Pluricompetent L3055 Burkittâ€™s Lymphoma Cells. Journal of Immunology, 2007, 179, 2705-2712.	0.8	14
124	Arginine Methyltransferases Are Regulated by Epstein-Barr Virus in B Cells and Are Differentially Expressed in Hodgkinâ€™s Lymphoma. Pathogens, 2012, 1, 52-64.	2.8	14
125	Stimulation of human lymphocytes with irradiated cells of the autologous Epstein-Barr virus-transformed cell line. Cellular Immunology, 1982, 67, 141-151.	3.0	13
126	Epstein-Barr virus latent genes in tumour cells of Hodgkin's disease. Lancet, The, 1991, 337, 1617.	13.7	13

#	Article	IF	Citations
127	Cytogenetic Rearrangement of C-MYC Oncogene Occurs Prior to Infection with Epstein-Barr Virus in the Monoclonal Malignant B Cells From an AIDS Patient. Leukemia and Lymphoma, 1993, 9, 157-164.	1.3	13
128	MHC class II-restricted presentation of endogenously synthesized antigen: Epstein-Barr virus transformed B cell lines can present the viral glycoprotein gp340 by two distinct pathways. International Immunology, 1993, 5, 451-460.	4.0	13
129	Susceptibility of B lymphocytes to adenovirus type 5 infection is dependent upon both coxsackieâ€“adenovirus receptor and Î±vÎ²5 integrin expression. Journal of General Virology, 2005, 86, 1669-1679.	2.9	13
130	Epstein-Barr virus transforming proteins. Seminars in Virology, 1994, 5, 391-399.	3.9	12
131	STAT1 contributes to the maintenance of the latency III viral programme observed in Epstein-Barr virus-transformed B cells and their recognition by CD8+ T cells. Journal of General Virology, 2009, 90, 2239-2250.	2.9	12
132	Induction of Interferon-Stimulated Genes on the IL-4 Response Axis by Epstein-Barr Virus Infected Human B Cells; Relevance to Cellular Transformation. PLoS ONE, 2013, 8, e64868.	2.5	12
133	Epstein-barr virus latent membrane protein-1 mediates upregulation of tumor necrosis factor-Î± in EBV-infected T cells: Implications for the pathogenesis of hemophagocytic syndrome. Journal of Biomedical Science, 2003, 10, 146-155.	7.0	11
134	Hypomethylation and Over-Expression of the Beta Isoform of BLIMP1 is Induced by Epstein-Barr Virus Infection of B Cells; Potential Implications for the Pathogenesis of EBV-Associated Lymphomas. Pathogens, 2012, 1, 83-101.	2.8	10
135	Epstein-barr virus-specific t-cell recognition of B-cell transformants expressing different ebna 2 antigens. International Journal of Cancer, 1987, 39, 373-379.	5.1	9
136	The level of expression of class-I MHC antigens in adenovirus-transformed human cell lines. International Journal of Cancer, 1987, 40, 213-219.	5.1	9
137	Lymphoblastoid cells transfected with c-myc: Downregulation of EBV-lytic antigens and impaired response of autologousCD4+ T cellsin vitro. , 1996, 68, 810-816.		8
138	Cross-recognition of a mouse H-2-peptide complex by human HLA-restricted cytotoxic T cells. European Journal of Immunology, 1990, 20, 659-664.	2.9	7
139	Analysis of human tumour necrosis factor receptor 1 dominant-negative mutants reveals a major region controlling cell surface expression. FEBS Letters, 2004, 570, 138-142.	2.8	7
140	Cell transformation induced by Epsteinâ€“Barr virusâ€"living dangerously. Seminars in Cancer Biology, 2001, 11, 403-405.	9.6	6
141	Detection of EBV Latent Proteins by Western Blotting. , 2001, 174, 229-242.		6
142	Burkitt-like lymphoma in an English child: Characterisation of tumour biopsy cells and of the derived tumour cell line. British Journal of Cancer, 1986, 54, 385-391.	6.4	5
143	Selective reactivation of Epstein-Barr virus-specific cytotoxic T cells by stimulation in vitro with allogeneic virus-transformed HLA-homozygous typing cells. Human Immunology, 1983, 6, 151-165.	2.4	4
144	Restoration of the LFA-3 adhesion pathway in Burkitt's lymphoma cells using an LFA-3 recombinant vaccinia virus: consequences for T cell recognition. European Journal of Immunology, 1992, 22, 1741-1748.	2.9	4

#	Article	IF	Citations
145	The Epstein-Barr Virus BamHI C Promoter Is Not Essential for B Cell ImmortalizationIn Vitro, but It Greatly Enhances B Cell Growth Transformation. Journal of Virology, 2015, 89, 2483-2493.	3.4	4
146	Human Lymphocyte Ecto-5â€²-Nucleotidase is Not Directly Involved in Immunoglobulin Production. Biochemical Society Transactions, 1979, 7, 997-998.	3.4	3
147	Characterization of a CD40-Dominant Inhibitory Receptor Mutant. Journal of Immunology, 2001, 167, 6388-6393.	0.8	3
148	Three Restricted Forms of Epstein-Barr Virus Latency Counteracting Apoptosis in c-Myc Expressing Burkitt Lymphoma Cells.. Blood, 2007, 110, 1572-1572.	1.4	2
149	Epstein-Barr virus gene expression in post-transplant lymphoproliferative disorders. Seminars in Immunopathology, 1998, 20, 389-403.	4.0	1
150	EBV, molecular mimicry and rheumatoid arthritis: a hypothesis. Immunology Letters, 1989, 20, 93.	2.5	0
151	Immunity to Oncogenic Viruses. , 2016, , 363-374.		0